Trial · NCT02567656
Results by group28
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 28
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Safety of RP6530 | Dose escalation_Cohort 1_200 mg | No.of Participants with Dose Limiting Toxicities | 0 | Participants | |
| Safety of RP6530 | Dose escalation_Cohort 2_400 mg | No.of Participants with Dose Limiting Toxicities | 0 | Participants | |
| Safety of RP6530 | Dose escalation_Cohort 3_800 mg (Fasting) | No.of Participants with Dose Limiting Toxicities | 0 | Participants | |
| Safety of RP6530 | Dose escalation_Cohort 4_800 mg (Fed) | No.of Participants with Dose Limiting Toxicities | 2 | Participants | |
| Safety of RP6530 | Dose expansion_PTCL_800 mg (Fasting) | No.of Participants with Dose Limiting Toxicities | 0 | Participants | |
| Safety of RP6530 | Dose expansion_CTCL_800 mg (Fasting) | No.of Participants with Dose Limiting Toxicities | 0 | Participants | |
| Safety of RP6530 | Dose escalation_Cohort 1_200 mg | No.of Participants without Dose Limiting Toxicitie | 4 | Participants | |
| Safety of RP6530 | Dose escalation_Cohort 2_400 mg | No.of Participants without Dose Limiting Toxicitie | 4 | Participants | |
| Safety of RP6530 | Dose escalation_Cohort 3_800 mg (Fasting) | No.of Participants without Dose Limiting Toxicitie | 5 | Participants | |
| Safety of RP6530 | Dose escalation_Cohort 4_800 mg (Fed) | No.of Participants without Dose Limiting Toxicitie | 4 | Participants | |
| Safety of RP6530 | Dose expansion_PTCL_800 mg (Fasting) | No.of Participants without Dose Limiting Toxicitie | 0 | Participants | |
| Safety of RP6530 | Dose expansion_CTCL_800 mg (Fasting) | No.of Participants without Dose Limiting Toxicitie | 0 | Participants | |
| Overall Response Rate (ORR) With RP6530 | Dose escalation_Cohort 1_200 mg | 1 | Participants | ||
| Overall Response Rate (ORR) With RP6530 | Dose escalation_Cohort 2_400 mg | 2 | Participants | ||
| Overall Response Rate (ORR) With RP6530 | Dose escalation_Cohort 3_800 mg (Fasting) | 2 | Participants | ||
| Overall Response Rate (ORR) With RP6530 | Dose escalation_Cohort 4_800 mg (Fed) | 2 | Participants | ||
| Overall Response Rate (ORR) With RP6530 | Dose expansion_PTCL_800 mg (Fasting) | 4 | Participants | ||
| Overall Response Rate (ORR) With RP6530 | Dose expansion_CTCL_800 mg (Fasting) | 5 | Participants | ||
| Duration of Response (DOR) With RP6530 | Dose escalation_Cohort 1_200 mg | 147 | Full Range 147 to 147 | Days | |
| Duration of Response (DOR) With RP6530 | Dose escalation_Cohort 2_400 mg | 72 | Full Range 29 to 115 | Days |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02567656/results